Chen BH, Zhu XM, Xie L, Hu HQ. Immune-mediated necrotizing myopathy: Report of two cases. World J Clin Cases 2023; 11(15): 3552-3559 [PMID: 37383916 DOI: 10.12998/wjcc.v11.i15.3552]
Corresponding Author of This Article
Huai-Qiang Hu, PhD, Doctor, Department of Neurology, The 960th Hospital of People′s Liberation Army, No. 25 Normal Road, Tianqiao District, Jinan 250031, Shandong Province, China. huhuaiqiang@126.com
Research Domain of This Article
Clinical Neurology
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. May 26, 2023; 11(15): 3552-3559 Published online May 26, 2023. doi: 10.12998/wjcc.v11.i15.3552
Immune-mediated necrotizing myopathy: Report of two cases
Bi-Hong Chen, Xue-Min Zhu, Lei Xie, Huai-Qiang Hu
Bi-Hong Chen, Department of Clinical Medicine, Weifang Medical University, Weifang 261053, Shandong Province, China
Xue-Min Zhu, Lei Xie, School of Clinical Medicine, Weifang Medical University, Weifang 261053, Shandong Province, China
Huai-Qiang Hu, Department of Neurology, The 960th Hospital of People′s Liberation Army, Jinan 250031, Shandong Province, China
Author contributions: Chen BH collected and sorted out the cases, reviewed the literature, and wrote the manuscript; Xie L and Zhu XM reviewed the literature; Hu HQ reviewed and revised the manuscript; all authors have read and approved the final manuscript.
Informed consent statement: The study participants provided informed written consent prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Huai-Qiang Hu, PhD, Doctor, Department of Neurology, The 960th Hospital of People′s Liberation Army, No. 25 Normal Road, Tianqiao District, Jinan 250031, Shandong Province, China. huhuaiqiang@126.com
Received: October 31, 2022 Peer-review started: October 31, 2022 First decision: February 14, 2023 Revised: February 25, 2023 Accepted: April 24, 2023 Article in press: April 24, 2023 Published online: May 26, 2023 Processing time: 206 Days and 2.4 Hours
Abstract
BACKGROUND
Immune-mediated necrotizing myopathy is a rare autoimmune myopathy characterized by muscle weakness and elevated serum creatine kinase, with unique skeletal muscle pathology and magnetic resonance imaging features.
CASE SUMMARY
In this paper, two patients are reported: One was positive for anti-signal recognition particle antibody, and the other was positive for anti-3-hydroxy-3-methylglutaryl coenzyme A reductase antibody.
CONCLUSION
The clinical characteristics and treatment of the two patients were analysed, and the literature was reviewed to improve the recognition, diagnosis, and treatment of this disease.
Core Tip: This paper describes two patients with different types of immune-mediated necrotizing myopathy, and compares the clinical features, imaging features, muscle pathology, and treatment of the two types in the discussion section, with an aim to further improve clinicians' understanding of the disease.
